Publicaciones en las que colabora con Inmaculada Jiménez Nácher (10)

2010

  1. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 543-547

  2. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  3. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

  4. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 8, pp. 1567-1569

2009

  1. Differences in lopinavir plasma concentrations comparing Kaletra® film coated tablets and soft gelatine capsules that result in various lipid abnormalities

    Drug Metabolism Letters, Vol. 3, Núm. 2, pp. 67-69

  2. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158

2008

  1. Association between tipranavir plasma levels and virological response in HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 3, pp. 389-391

2007

  1. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 11, pp. 1374-1376

2003

  1. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir

    AIDS Patient Care and STDs, Vol. 17, Núm. 9, pp. 443-445

2001

  1. Episodios oportunistas en pacientes infectados por el virus de la inmunodeficiencia humana durante los primeros 6 meses de la terapia antirretroviral de gran actividad

    Medicina Clinica, Vol. 117, Núm. 3, pp. 81-84